People | January 20, 2022
AstraZeneca India appoints Ram Mudaliar as India lead of their CDI division
Ram’s appointment follows the launch of the CDI India division in October 2021.
Ram’s appointment follows the launch of the CDI India division in October 2021.
This surpasses the number of approvals supported in 2020
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
